^
    15h
    Registry of Patients Undergoing Cryoablation for Early Stage Breast Cancer (clinicaltrials.gov)
    P=N/A, N=2, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial primary completion date: Jan 2025 --> Jan 2027
    Trial primary completion date
    15h
    LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study (clinicaltrials.gov)
    P=N/A, N=75, Recruiting, University of Alberta | Trial primary completion date: Nov 2025 --> Jun 2026
    Trial primary completion date
    16h
    Brain Health in Breast Cancer Survivors (clinicaltrials.gov)
    P=N/A, N=120, Recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Mar 2027 --> Mar 2028 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    16h
    INFLUENCE II: Evaluate the Implementation of Using Indocyanine Green for Sentinel Lymph Node Mapping in Breast Cancer Patients (clinicaltrials.gov)
    P=N/A, N=40, Recruiting, Casa di Cura Dott. Pederzoli | Trial completion date: Mar 2026 --> Oct 2026
    Trial completion date
    17h
    A Phase 1 Study of IM-1617 in Participants With Advanced Cancer (clinicaltrials.gov)
    P1, N=175, Not yet recruiting, Immunome, Inc.
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PGR (Progesterone receptor) • PD-1 (Programmed cell death 1)
    |
    HER-2 negative • RAS wild-type
    17h
    Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) (clinicaltrials.gov)
    P1/2, N=1410, Active, not recruiting, Klus Pharma Inc. | Trial completion date: Jul 2026 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    HER-2 negative • HER-2 expression • HER-2 negative + ER positive
    |
    Jiataile (sacituzumab tirumotecan)
    18h
    PM14 Administered Intravenously to Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=126, Completed, PharmaMar | Recruiting --> Completed
    Trial completion • First-in-human
    |
    BRCA (Breast cancer early onset)
    |
    BRCA mutation
    |
    ecubectedin (PM14)
    18h
    Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis (clinicaltrials.gov)
    P3, N=562, Not yet recruiting, SWOG Cancer Research Network
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Trazimera (trastuzumab-qyyp) • Paletan (pertuzumab biosimilar) • Pertuvia (pertuzumab biosimilar) • Poherdy (pertuzumab-dpzb)
    19h
    Multidisciplinary Team IntervenTion in CArdio-ONcology (TITAN Study) (clinicaltrials.gov)
    P2, N=80, Active, not recruiting, University of Alberta | Trial completion date: Jun 2025 --> Dec 2026
    Trial completion date
    20h
    Breast Cancer - Navigate - Prospective Cohort (clinicaltrials.gov)
    P=N/A, N=64, Completed, Northwestern University | Recruiting --> Completed | N=150 --> 64 | Trial completion date: Jun 2025 --> Sep 2025 | Trial primary completion date: Jun 2025 --> Sep 2025
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date
    20h
    UCLA B-13: Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer (clinicaltrials.gov)
    P1/2, N=18, Active, not recruiting, Jonsson Comprehensive Cancer Center | Trial completion date: Apr 2027 --> Apr 2028 | Trial primary completion date: Apr 2026 --> Apr 2027 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    HER-2 amplification
    |
    carboplatin • docetaxel • Perjeta (pertuzumab) • Kisqali (ribociclib) • fulvestrant • Tukysa (tucatinib) • Herzuma (trastuzumab-pkrb) • Trazimera (trastuzumab-qyyp)
    20h
    A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer (clinicaltrials.gov)
    P2, N=150, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki) • trastuzumab rezetecan (SHR-A1811)